Showing results (371-380 of 1,543) with videos related to
Sort By:
Pageof 155
Cancer Reports (Hoboken, N.J.)|July 12, 2023
The impact of the COVID-19 pandemic on the diagnosis and treatment of skin cancers, a mini reviewZeinab Aryanian, Kamran Balighi, Azadeh Goodarzi, et al.Cancer Reports (Hoboken, N.J.)|July 5, 2023
Effect of bariatric surgery on endometrial cancer regression as part of fertility sparing treatmentJinlin Lin, Weng Yan Ho, Qi Xuan Lim, et al.Cancer Reports (Hoboken, N.J.)|June 22, 2023
Current understanding and distinct features of multifocal and multicentric breast cancersElizabeth Avera, Lilia Valentic, Loan BuiCancer Reports (Hoboken, N.J.)|June 8, 2023
Overview of glottic laryngeal cancer treatment recommendation changes in the NCCN guidelines from 2011 to 2022Lady Paola Aristizabal Arboleda, Aline Borburema Neves, Hugo Fontan Kohler, et al.Cancer Reports (Hoboken, N.J.)|July 15, 2026
Global Incidence, Risk Factors, and Trends of Pharyngeal Cancer by Anatomical Sites: A Systematic Analysis of Cancer RegistriesJunjie Huang, Sze Chai Chan, Wing Sze Pang, et al.Cancer Reports (Hoboken, N.J.)|June 18, 2026
Diabetes and Cancer-Specific Survival: A Nationwide Population-Based Cohort Study Across Multiple Cancer SitesPetrus Lohi, Jari Haukka, Leo Niskanen, et al.Cancer Reports (Hoboken, N.J.)|June 20, 2026
Dance and Dietary Intervention Improves Metabolic Health, Fitness, and Quality of Life With Modest Gut Microbiota Shifts in Breast Cancer Patients With Obesity: A Pilot RCTLibuša Nechalová, Adela Penesová, Ivan Hric, et al.Cancer Reports (Hoboken, N.J.)|July 2, 2026
Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case SeriesHonghu Li, Luxin Yang, Lizhen Liu, et al.Cancer Reports (Hoboken, N.J.)|July 2, 2026
Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial DesignNada O Othman, Hadir Habib, Doaa M Almeldin, et al.Cancer Reports (Hoboken, N.J.)|May 17, 2022
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse eventsJaume Mora, Godfrey C Chan, Daniel A Morgenstern, et al.Pageof 155